https://www.prnewswire.com/news-releases/inovio-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301911827.html
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
h cinoviopresentwainwrightannual
https://www.macrotrends.net/stocks/charts/INO/inovio-pharmaceuticals/ebitda
Inovio Pharmaceuticals ebitda from 2012 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
inovio pharmaceuticalsebitdamacrotrends
https://finviz.com/news/263342/fda-accepts-for-review-inovios-bla-for-ino-3107-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-rrp
Stock screener for investors and traders, financial visualizations.
fdaacceptsreviewinoviobla
https://www.pharmaceutical-technology.com/data-insights/inovio-pharmaceuticals-gets-grant-for-electroporation-device-with-adjustable-needle-array-auto-lock-assembly-2/
Enhance electroporation procedures with Inovio Pharmaceuticals' patented needle array device. Precise control and secure drug delivery for optimal results.
meta titleinovio pharmaceuticalspatent filingincelectroporation
https://www.macrotrends.net/stocks/charts/INO/inovio-pharmaceuticals/total-share-holder-equity
Inovio Pharmaceuticals share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
inovio pharmaceuticalsshare holderequitymacrotrends
https://www.prnewswire.com/news-releases/roche-and-inovio-pharmaceuticals-partner-on-inovios-prostate-cancer-and-hepatitis-b-immunotherapy-products-223082671.html
/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they have entered into an exclusive...
inovio pharmaceuticalsprostate cancerrochepartner